11C-Choline Pharmacokinetics in Recurrent Prostate Cancer

被引:6
|
作者
Grkovski, Milan [1 ]
Gharzeddine, Karem [2 ]
Sawan, Peter [2 ]
Schoeder, Heiko [2 ,3 ]
Michaud, Laure [2 ]
Weber, Wolfgang A. [2 ,3 ,4 ]
Humm, John L. [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Med Phys, 1275 York Ave, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA
[3] Mem Sloan Kettering Canc Ctr, Mol Imaging & Therapy Serv, 1275 York Ave, New York, NY 10021 USA
[4] Tech Univ Munich, Klinikum Rechts Isar, Univ Hosp, Munich, Germany
关键词
C-11-choline; dynamic PET; kinetic modeling; prostate cancer; metastasis; EMISSION-TOMOGRAPHY; BLOOD-FLOW; CHOLINE; PET; METASTASES; METABOLISM; MECHANISMS; CARCINOMA; KINETICS;
D O I
10.2967/jnumed.118.210088
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The aim of this study was to investigate the value of pharmacokinetic modeling for quantifying 11C-choline uptake in patients with recurrent prostate cancer. Methods: In total, 194 patients with clinically suspected recurrence of prostate cancer underwent 11C-choline dynamic PET over the pelvic region (0-8 min), followed by a 6-min static acquisition at about 25 min after injection. Regions of interest were drawn over sites of disease identified by a radiologist with experience in nuclear medicine. 11C-choline uptake and pharmacokinetics were evaluated by SUV, graphical analysis (Patlak plot; Ki P), and 1-and 2-compartment pharmacokinetic models (K1, K1/k2, k3, k4, and the macro parameter Ki C). Twenty-four local recurrences, 65 metastatic lymph nodes, 19 osseous metastases, and 60 inflammatory lymph nodes were included in the analysis, which was subsequently repeated for regions of interest placed over the gluteus maximus muscle and adipose tissue as a control. Results: SUVmean and Ki P were 3.60 +/- 2.16 and 0.28 +/- 0.22 min(-1) in lesions, compared with 2.11 +/- 1.33 and 0.15 +/- 0.10 min(-1) in muscle and 0.26 +/- 0.07 and 0.02 +/- 0.01 min(-1) in adipose tissue. According to the Akaike information criterion, the 2-compartment irreversible model was most appropriate in 85% of lesions and resulted in a K1 of 0.79 +/- 0.98 min(-1) (range, 0.11-7.17 min(-1)), a K1/k2 of 2.92 +/- 3.52 (range, 0.31-20.00), a k3 of 0.36 +/- 0.30 min(-1) (range, 0.00(-1).00 min(-1)) and a Ki C of 0.28 +/- 0.22 min(-1) (range, 0.00-1.33 min(-1)). The Spearman. between SUV and Ki P, between SUV and Ki C, and between Ki P and Ki C was 0.94, 0.91, and 0.97, respectively, and that between SUV and K1, between SUV and K1/k2, and between SUV and k3 was 0.70, 0.44, and 0.33, respectively. Malignant lymph nodes exhibited a higher SUV, Ki P, and Ki C than benign lymph nodes. Conclusion: Although 11C-choline pharmacokinetic modeling has potential to uncouple the contributions of different processes leading to intracellular entrapment of 11C-choline, the high correlation between SUV and both Ki P and Ki C supports the use of simpler SUV methods to evaluate changes in 11C-choline uptake and metabolism for treatment monitoring.
引用
收藏
页码:1672 / 1678
页数:7
相关论文
共 50 条
  • [1] 11C-choline pharmacokinetics in recurrent prostate cancer
    Grkovski, M.
    Gharzeddine, K.
    Sawan, P.
    Schoder, H.
    Weber, W. A.
    Humm, J. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S552 - S552
  • [2] 11C-Choline PET/CT in Recurrent Prostate Cancer
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2013, 54 (01) : 24N - 24N
  • [3] 11C-Choline PET/CT imaging for localization of recurrent prostate cancer
    Farsad, M
    Castellucci, P
    Nanni, C
    Fanti, S
    Schiavina, R
    Malfatti, V
    Pontone, G
    Battista, G
    Zagni, P
    Salizzoni, E
    Monetti, N
    Martorana, G
    Canini, R
    Franchi, R
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S252 - S252
  • [4] 11C-Choline PET/CT in Recurrent Prostate Cancer and Nonprostatic Neoplastic Processes
    Welle, Christopher L.
    Cullen, Ethany L.
    Peller, Patrick J.
    Lowe, Val J.
    Murphy, Robert C.
    Johnson, Geoffrey B.
    Binkovitz, Larry A.
    RADIOGRAPHICS, 2016, 36 (01) : 279 - 292
  • [5] Is 11C-choline the most appropriate tracer for prostate cancer?
    Fazio, F
    Picchio, M
    Messa, C
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 (05) : 753 - 756
  • [6] Is 11C-choline the most appropriate tracer for prostate cancer?
    Ferruccio Fazio
    Maria Picchio
    Cristina Messa
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 753 - 755
  • [7] FDA Approves 11C-Choline for PET in Prostate Cancer
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (12) : 11N - 11N
  • [8] Is 11C-choline the most appropriate tracer for prostate cancer?
    Klaus Zöphel
    Jörg Kotzerke
    European Journal of Nuclear Medicine and Molecular Imaging, 2004, 31 : 756 - 759
  • [9] Imaging prostate cancer with 11C-choline PET/CT
    Reske, Sven N.
    Blumstein, Norbert M.
    Neumaier, Bernd
    Gottfried, Hans-Werner
    Finsterbusch, Frank
    Kocot, Darius
    Moeller, Peter
    Glatting, Gerhard
    Perner, Sven
    JOURNAL OF NUCLEAR MEDICINE, 2006, 47 (08) : 1249 - 1254
  • [10] 11C-choline PET/CT in selection of patients for salvage cryoablation in recurrent prostate cancer
    Breeuwsma, Anthonius J.
    Rybalov, Maxim
    Leliveld, Anna Maria
    Dierckx, Rudi A.
    Pruim, Jan
    de Jong, Igle J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)